These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35600796)

  • 21. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
    Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis.
    Saha A; Dreyfuss I; Sarfraz H; Friedman M; Markowitz J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
    Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
    Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
    Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
    Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-Mediated Colitis.
    Menon T; Afzali A
    Curr Treat Options Gastroenterol; 2019 Dec; 17(4):506-523. PubMed ID: 31741212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management.
    Fattore D; Battista T; De Lucia M; Annunziata MC; Fabbrocini G
    Case Rep Dermatol; 2022; 14(2):225-229. PubMed ID: 36158854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study.
    Wang L; Li X; Zhao B; Mei D; Jiang J; Duan J
    Front Pharmacol; 2021; 12():679207. PubMed ID: 34630077
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
    Braga Neto MB; Ramos GP; Loftus EV; Faubion WA; Raffals LE
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1285-1287.e1. PubMed ID: 32565289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
    Nakamura Y
    Front Med (Lausanne); 2019; 6():119. PubMed ID: 31192215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Meserve J; Facciorusso A; Holmer AK; Annese V; Sandborn WJ; Singh S
    Aliment Pharmacol Ther; 2021 Feb; 53(3):374-382. PubMed ID: 33314269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
    Xiong W; Zhao Y; Du H; Guo X
    Front Oncol; 2021; 11():704336. PubMed ID: 34490104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review.
    Yin N; Liu X; Ye X; Song W; Lu J; Chen X
    Front Oncol; 2022; 12():961266. PubMed ID: 36119464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.